WHAT IS CLAIMED IS:

1. A bispecific ribonucleic acid (RNA) aptamer comprising a nucleotide sequence selected from the group consisting of SEQ ID Nos. 69-71 and 74-76.

2. The bispecific RNA aptamer of claim 1, wherein one or more nucleotides of the bispecific RNA aptamer are further chemically modified.

3. The bispecific RNA aptamer of claim 2, wherein the one or more further chemically modified nucleotides are selected from the group consisting of 2'Fluoro (2'F) Guanosine, 2' OMe Guanosine, 2'OMe Adenosine, 2'OMe Cytosine, 2'OMe Uridine and combinations thereof.

4. The bispecific RNA aptamer of claim 1, wherein the bispecific RNA aptamer specifically binds to Vascular Endothelial Growth Factor (VEGF) or an isoform thereof and Interleukin 8 (IL8).

5. The bispecific RNA aptamer of claim 4, wherein the bispecific RNA aptamer inhibits the function of VEGF or an isoform thereof and IL8 by an amount between 90% and 100%.

6. The bispecific RNA aptamer of any one of claims 1-5, wherein the bispecific RNA aptamer is attached directly to polyethylene glycol (PEG).

7. The bispecific RNA aptamer of claim 6, wherein the bispecific RNA aptamer has a hydrodynamic radius greater than 10 nm.

8. A pharmaceutical composition comprising the bispecific RNA aptamer of any one of claims 1-7 and a pharmaceutically acceptable carrier.

9. The pharmaceutical composition of claim 8, formulated for intravitreal administration.

10. Use of the bispecific RNA aptamer of any one of claims 1-7 or the pharmaceutical composition of claim 8 or 9 in the manufacture of a medicament for treating a retinal disease or disorder in a subject in need thereof, wherein the medicament is for intravitreal injection.

11. The use of claim 10, wherein the retinal disease or disorder is selected from the group consisting of the wet form of age-related macular degeneration (wAMD), diabetic retinopathy, diabetic macular edema, retinal vein occlusion, retinopathy of prematurity and radiation retinopathy

12. The use of claim 10 or 11, wherein the subject in need thereof has been previously treated with one or more anti-VEGF agents, but where the subject has shown a suboptimal response to such treatment.